Overview

ULTRATRACE Iobenguane I 131 in Patients With Malignant Pheochromocytoma, Paraganglioma, or Metastatic Carcinoid

Status:
Completed
Trial end date:
2007-01-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to test the safety of a drug called Ultratrace iobenguane I 131 that has radioactivity, to measure how long it takes for the drug to be absorbed and passed out of the body, and to measure how much radioactivity is absorbed into different tissues of the body.
Phase:
Phase 1
Details
Lead Sponsor:
Molecular Insight Pharmaceuticals, Inc.
Treatments:
3-Iodobenzylguanidine